Search

Your search keyword '"Laaksonen, Reijo"' showing total 427 results
Start Over Author "Laaksonen, Reijo" Publication Type Academic Journals
427 results on '"Laaksonen, Reijo"'

9. Abstract 12514: Ceramide-Based Lipid Profiles and the Prevalence of Type 2 Diabetes Differ Between Patients With Coronary Artery Disease and Those With Peripheral Artery Disease

Author

Leiherer, Andreas, Muendlein, Axel, Brandtner, Eva Maria, Saely, Christoph H, Vonbank, Alexander, Mader, Arthur, Sprenger, Lukas, Maechler, Maximilian, Larcher, Barbara, Jylha, Antti, Laaperi, Mitja, Laaksonen, Reijo, Maerz, Winfried, Fraunberger, Peter, Kleber, Marcus, and Drexel, Heinz

Published
2022
Full Text
View/download PDF

12. Systems Genetics Analysis of Genome-Wide Association Study Reveals Novel Associations Between Key Biological Processes and Coronary Artery Disease

Author

Ghosh, Sujoy, Vivar, Juan, Nelson, Christopher P, Willenborg, Christina, Segrè, Ayellet V, Mäkinen, Ville-Petteri, Nikpay, Majid, Erdmann, Jeannette, Blankenberg, Stefan, O'Donnell, Christopher, März, Winfried, Laaksonen, Reijo, Stewart, Alexandre FR, Epstein, Stephen E, Shah, Svati H, Granger, Christopher B, Hazen, Stanley L, Kathiresan, Sekar, Reilly, Muredach P, Yang, Xia, Quertermous, Thomas, Samani, Nilesh J, Schunkert, Heribert, Assimes, Themistocles L, and McPherson, Ruth

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Heart Disease - Coronary Heart Disease, Cardiovascular, Genetics, Human Genome, Atherosclerosis, Heart Disease, Aetiology, 2.1 Biological and endogenous factors, Underpinning research, 1.1 Normal biological development and functioning, Coronary Artery Disease, Genome-Wide Association Study, Humans, coronary artery disease, pathway analysis, Cardiorespiratory Medicine and Haematology, Cardiovascular System & Hematology, Cardiovascular medicine and haematology, Clinical sciences
Abstract

ObjectiveGenome-wide association studies have identified multiple genetic variants affecting the risk of coronary artery disease (CAD). However, individually these explain only a small fraction of the heritability of CAD and for most, the causal biological mechanisms remain unclear. We sought to obtain further insights into potential causal processes of CAD by integrating large-scale GWA data with expertly curated databases of core human pathways and functional networks.Approaches and resultsUsing pathways (gene sets) from Reactome, we carried out a 2-stage gene set enrichment analysis strategy. From a meta-analyzed discovery cohort of 7 CAD genome-wide association study data sets (9889 cases/11 089 controls), nominally significant gene sets were tested for replication in a meta-analysis of 9 additional studies (15 502 cases/55 730 controls) from the Coronary ARtery DIsease Genome wide Replication and Meta-analysis (CARDIoGRAM) Consortium. A total of 32 of 639 Reactome pathways tested showed convincing association with CAD (replication P

Published
2015

16. Integrative genomics reveals novel molecular pathways and gene networks for coronary artery disease.

Author

Mäkinen, Ville-Petteri, Civelek, Mete, Meng, Qingying, Zhang, Bin, Zhu, Jun, Levian, Candace, Huan, Tianxiao, Segrè, Ayellet V, Ghosh, Sujoy, Vivar, Juan, Nikpay, Majid, Stewart, Alexandre FR, Nelson, Christopher P, Willenborg, Christina, Erdmann, Jeanette, Blakenberg, Stefan, O'Donnell, Christopher J, März, Winfried, Laaksonen, Reijo, Epstein, Stephen E, Kathiresan, Sekar, Shah, Svati H, Hazen, Stanley L, Reilly, Muredach P, Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) Consortium, Lusis, Aldons J, Samani, Nilesh J, Schunkert, Heribert, Quertermous, Thomas, McPherson, Ruth, Yang, Xia, and Assimes, Themistocles L

Subjects
Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) Consortium, Animals, Humans, Mice, Genetic Predisposition to Disease, Genomics, Signal Transduction, Gene Expression Regulation, Gene Regulatory Networks, Coronary Artery Disease, Genome-Wide Association Study, Developmental Biology, Genetics
Abstract

The majority of the heritability of coronary artery disease (CAD) remains unexplained, despite recent successes of genome-wide association studies (GWAS) in identifying novel susceptibility loci. Integrating functional genomic data from a variety of sources with a large-scale meta-analysis of CAD GWAS may facilitate the identification of novel biological processes and genes involved in CAD, as well as clarify the causal relationships of established processes. Towards this end, we integrated 14 GWAS from the CARDIoGRAM Consortium and two additional GWAS from the Ottawa Heart Institute (25,491 cases and 66,819 controls) with 1) genetics of gene expression studies of CAD-relevant tissues in humans, 2) metabolic and signaling pathways from public databases, and 3) data-driven, tissue-specific gene networks from a multitude of human and mouse experiments. We not only detected CAD-associated gene networks of lipid metabolism, coagulation, immunity, and additional networks with no clear functional annotation, but also revealed key driver genes for each CAD network based on the topology of the gene regulatory networks. In particular, we found a gene network involved in antigen processing to be strongly associated with CAD. The key driver genes of this network included glyoxalase I (GLO1) and peptidylprolyl isomerase I (PPIL1), which we verified as regulatory by siRNA experiments in human aortic endothelial cells. Our results suggest genetic influences on a diverse set of both known and novel biological processes that contribute to CAD risk. The key driver genes for these networks highlight potential novel targets for further mechanistic studies and therapeutic interventions.

Published
2014

17. Ceramides: a potential cardiovascular biomarker in young adult childhood cancer survivors?

Author

Broberg, Olof, Weismann, Constance G., Øra, Ingrid, Wiebe, Thomas, Laaksonen, Reijo, and Liuba, Petru

Subjects
YOUNG adults, CERAMIDES, CHILDHOOD cancer, CANCER survivors, CANCER patients
Abstract

Aims: The aim of this study was to investigate circulating ceramides involved in cardiovascular disease (CVD) in young adult childhood cancer survivors (CCS) and their correlations to previously reported adverse cardiovascular changes in this cohort. Methods and results: Fifty-seven CCS and 53 healthy controls (age 20-30 years) were studied. Plasma long-chain ceramides, known to be cardiotoxic (C16:0, C18:0, C24:0, and C24:1), were analysed by mass spectrometry. The coronary event risk test 2 (CERT2) score was calculated from the ceramide data. Cardiac and carotid artery ultrasound data and lipid data available from previous studies of this cohort were used to study partial correlations with ceramide and CERT2 score data. All four analysed ceramides were elevated in CCS compared with controls (P ≤ 0.012). The greatest difference was noted for C18:0, which was 33% higher in CCS compared with controls adjusted for sex, age, and body mass index (BMI) (P < 0.001). The CERT2 score was higher in CCS compared with controls (P < 0.001). In the CCS group, 35% had a high to very high CERT2 score (7-12) when compared with 9% in the control group (P < 0.001). The CCS subgroup with a CERT2 score ≥ 7 had higher heart rate, systolic blood pressure, and higher levels of apolipoprotein B compared with CCS with a CERT2 score < 6 (P ≤ 0.011). When adjusted for age, sex, and BMI, CERT2 score was significantly correlated with arterial stiffness, growth hormone, and cranial radiotherapy (P < 0.044). Conclusion: Ceramides could be important biomarkers in understanding the pathophysiology of CVD and in predicting CVD disease risk in young adult CCS. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study

Author

Zewinger, Stephen, Kleber, Marcus E, Tragante, Vinicius, McCubrey, Raymond O, Schmidt, Amand F, Direk, Kenan, Laufs, Ulrich, Werner, Christian, Koenig, Wolfgang, Rothenbacher, Dietrich, Mons, Ute, Breitling, Lutz P, Brenner, Herrmann, Jennings, Richard T, Petrakis, Ioannis, Triem, Sarah, Klug, Mira, Filips, Alexandra, Blankenberg, Stefan, Waldeyer, Christoph, Sinning, Christoph, Schnabel, Renate B, Lackner, Karl J, Vlachopoulou, Efthymia, Nygård, Ottar, Svingen, Gard Frodahl Tveitevåg, Pedersen, Eva Ringdal, Tell, Grethe S, Sinisalo, Juha, Nieminen, Markku S, Laaksonen, Reijo, Trompet, Stella, Smit, Roelof A J, Sattar, Naveed, Jukema, J Wouter, Groesdonk, Heinrich V, Delgado, Graciela, Stojakovic, Tatjana, Pilbrow, Anna P, Cameron, Vicky A, Richards, A Mark, Doughty, Robert N, Gong, Yan, Cooper-DeHoff, Rhonda, Johnson, Julie, Scholz, Markus, Beutner, Frank, Thiery, Joachim, Smith, J Gustav, Vilmundarson, Ragnar O, McPherson, Ruth, Stewart, Alexandre F R, Cresci, Sharon, Lenzini, Petra A, Spertus, John A, Olivieri, Oliviero, Girelli, Domenico, Martinelli, Nicola I, Leiherer, Andreas, Saely, Christoph H, Drexel, Heinz, Mündlein, Axel, Braund, Peter S, Nelson, Christopher P, Samani, Nilesh J, Kofink, Daniel, Hoefer, Imo E, Pasterkamp, Gerard, Quyyumi, Arshed A, Ko, Yi-An, Hartiala, Jaana A, Allayee, Hooman, Tang, W H Wilson, Hazen, Stanley L, Eriksson, Niclas, Held, Claes, Hagström, Emil, Wallentin, Lars, Åkerblom, Axel, Siegbahn, Agneta, Karp, Igor, Labos, Christopher, Pilote, Louise, Engert, James C, Brophy, James M, Thanassoulis, George, Bogaty, Peter, Szczeklik, Wojciech, Kaczor, Marcin, Sanak, Marek, Virani, Salim S, Ballantyne, Christie M, Lee, Vei-Vei, Boerwinkle, Eric, Holmes, Michael V, Horne, Benjamin D, Hingorani, Aroon, Asselbergs, Folkert W, Patel, Riyaz S, Krämer, Bernhard K, Scharnagl, Hubert, Fliser, Danilo, März, Winfried, and Speer, Thimoteus

Published
2017
Full Text
View/download PDF

21. The Novel Ceramide- and Phosphatidylcholine-Based Risk Score for the Prediction of New-Onset of Hypertension.

Author

Shoghli, Mohammadreza, Lokki, A. Inkeri, Lääperi, Mitja, Sinisalo, Juha, Lokki, Marja-Liisa, Hilvo, Mika, Jylhä, Antti, Tuomilehto, Jaakko, and Laaksonen, Reijo

Subjects
DISEASE risk factors, LIQUID chromatography-mass spectrometry, CERAMIDES, HYPERTENSION, SPHINGOLIPIDS
Abstract

Ceramides and other sphingolipids are implicated in vascular dysfunction and inflammation. They have been suggested as potential biomarkers for hypertension. However, their specific association with hypertension prevalence and onset requires further investigation. This study aimed to identify specific ceramide and phosphatidylcholine species associated with hypertension prevalence and onset. The 2002 FINRISK (Finnish non-communicable risk factor survey) study investigated the association between coronary event risk scores (CERT1 and CERT2) and hypertension using prevalent and new-onset hypertension groups, both consisting of 7722 participants, over a span of 10 years. Ceramide and phosphatidylcholine levels were measured using tandem liquid chromatography-mass spectrometry. Ceramide and phosphatidylcholine ratios, including ceramide (d18:1/18:0), ceramide (d18:1/24:1), phosphatidylcholine (16:0/16:0), and the ratio of ceramide (d18:1/18:0)/(d18:1/16:0), are consistently associated with both prevalence and new-onset hypertension. Ceramide (d18:1/24:0) was also linked to both hypertension measures. Adjusting for covariates, CERT1 and CERT2 showed no-longer-significant associations with hypertension prevalence, but only CERT2 predicted new-onset hypertension. Plasma ceramides and phosphatidylcholines are crucial biomarkers for hypertension, with imbalances potentially contributing to its development. Further research is needed to understand the underlying mechanisms by which ceramides will contribute to the development of hypertension. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

23. Plasma concentrations of molecular lipid species in relation to coronary plaque characteristics and cardiovascular outcome: Results of the ATHEROREMO-IVUS study

Author

Cheng, Jin M., Suoniemi, Matti, Kardys, Isabella, Vihervaara, Terhi, de Boer, Sanneke P.M., Akkerhuis, K. Martijn, Sysi-Aho, Marko, Ekroos, Kim, Garcia-Garcia, Hector M., Oemrawsingh, Rohit M., Regar, Evelyn, Koenig, Wolfgang, Serruys, Patrick W., van Geuns, Robert-Jan, Boersma, Eric, and Laaksonen, Reijo

Published
2015
Full Text
View/download PDF

24. Whole blood microRNA levels associate with glycemic status and correlate with target mRNAs in pathways important to type 2 diabetes

Author

Mononen, Nina, Lyytikäinen, Leo-Pekka, Seppälä, Ilkka, Mishra, Pashupati P., Juonala, Markus, Waldenberger, Melanie, Klopp, Norman, Illig, Thomas, Leiviskä, Jaana, Loo, Britt-Marie, Laaksonen, Reijo, Oksala, Niku, Kähönen, Mika, Hutri-Kähönen, Nina, Raitakari, Olli, Lehtimäki, Terho, and Raitoharju, Emma

Published
2019
Full Text
View/download PDF

25. Coronary Event Risk Test (CERT) as a Risk Predictor for the 10-Year Clinical Outcome of Patients with Peripheral Artery Disease.

Author

Leiherer, Andreas, Muendlein, Axel, Saely, Christoph H., Geiger, Kathrin, Brandtner, Eva-Maria, Heinzle, Christine, Gaenger, Stella, Mink, Sylvia, Laaksonen, Reijo, Fraunberger, Peter, and Drexel, Heinz

Subjects
PERIPHERAL vascular diseases, DISEASE risk factors, CORONARY artery disease, TYPE 2 diabetes, STATINS (Cardiovascular agents)
Abstract

(1) Background: Ceramides are a new kind of lipid biomarker and have already been demonstrated to be valuable risk predictors in coronary patients. Patients with peripheral artery disease (PAD) are a population with a worse prognosis and higher mortality risk compared to coronary artery disease (CAD) patients. However, the value of ceramides for risk prediction in PAD patients is still vague, as addressed in the present study. (2)Methods: This observational study included 379 PAD patients. The primary endpoint was all-cause mortality at 10 years of follow-up. A set of ceramides was measured by LC-MS/MS and combined according to the Coronary Event Risk Test (CERT) score, which categorizes patients into one of four risk groups (low risk, moderate risk, high risk, very high risk). (3) Results: Kaplan–Meier survival curves revealed that the overall survival of patients decreased with the increasing risk predicted by the four CERT categories, advancing from low risk to very high risk. Cox regression analysis demonstrated that each one-category increase resulted in a 35% rise in overall mortality risk (HR = 1.35 [1.16–1.58]). Multivariable adjustment, including, among others, age, LDL-cholesterol, type 2 diabetes, and statin treatment before the baseline, did not abrogate this significant association (HR = 1.22 [1.04–1.43]). Moreover, we found that the beneficial effect of statin treatment is significantly stronger in patients with a higher risk, according to CERT. (4) Conclusions: We conclude that the ceramide-based risk score CERT is a strong predictor of the 10-year mortality risk in patients with PAD. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

28. Genetic variants primarily associated with type 2 diabetes are related to coronary artery disease risk

Author

Jansen, Henning, Loley, Christina, Lieb, Wolfgang, Pencina, Michael J., Nelson, Christopher P., Kathiresan, Sekar, Peloso, Gina M., Voight, Benjamin F., Reilly, Muredach P., Assimes, Themistocles L., Boerwinkle, Eric, Hengstenberg, Christian, Laaksonen, Reijo, McPherson, Ruth, Roberts, Robert, Thorsteinsdottir, Unnur, Peters, Annette, Gieger, Christian, Rawal, Rajesh, Thompson, John R., König, Inke R., Vasan, Ramachandran S., Erdmann, Jeanette, Samani, Nilesh J., and Schunkert, Heribert

Published
2015
Full Text
View/download PDF

33. A genome-wide expression quantitative trait loci analysis of proprotein convertase subtilisin/kexin enzymes identifies a novel regulatory gene variant for FURIN expression and blood pressure

Author

Turpeinen, Hannu, Seppälä, Ilkka, Lyytikäinen, Leo-Pekka, Raitoharju, Emma, Hutri-Kähönen, Nina, Levula, Mari, Oksala, Niku, Waldenberger, Melanie, Klopp, Norman, Illig, Thomas, Mononen, Nina, Laaksonen, Reijo, Raitakari, Olli, Kähönen, Mika, Lehtimäki, Terho, and Pesu, Marko

Published
2015
Full Text
View/download PDF

35. Effects of Cigarette Smoke, Cessation, and Switching to Two Heat-Not-Burn Tobacco Products on Lung Lipid Metabolism in C57BL/6 and Apoe−/− Mice—An Integrative Systems Toxicology Analysis

Author

Titz, Bjoern, Boué, Stéphanie, Phillips, Blaine, Talikka, Marja, Vihervaara, Terhi, Schneider, Thomas, Nury, Catherine, Elamin, Ashraf, Guedj, Emmanuel, Peck, Michael J., Schlage, Walter K., Cabanski, Maciej, Leroy, Patrice, Vuillaume, Gregory, Martin, Florian, Ivanov, Nikolai V., Veljkovic, Emilija, Ekroos, Kim, Laaksonen, Reijo, Vanscheeuwijck, Patrick, Peitsch, Manuel C., and Hoeng, Julia

Published
2016
Full Text
View/download PDF

37. Circulating trimethylamine N‐oxide levels do not predict 10‐year survival in patients with or without coronary heart disease.

Author

Bjørnestad, Espen Ø., Dhar, Indu, Svingen, Gard F. T., Pedersen, Eva R., Ørn, Stein, Svenningsson, Mads M., Tell, Grethe S., Ueland, Per M., Sulo, Gerhard, Laaksonen, Reijo, and Nygård, Ottar

Subjects
CORONARY disease, HEART disease related mortality, OVERALL survival, TRIMETHYLAMINE, CORONARY artery disease
Abstract

Background: Trimethylamine N‐oxide (TMAO) is an amine oxide generated by gut microbial metabolism. TMAO may contribute to atherothrombosis and systemic inflammation. However, the prognostic value of circulating TMAO for risk stratification is uncertain. Methods: We assessed prospective relationships of plasma TMAO with long‐term risk of all‐cause, cardiovascular (CV), and non‐CV mortality in the Western Norway Coronary Angiography Cohort (WECAC; 4132 patients with suspected coronary artery disease) and the Hordaland Health Study (HUSK; 6393 community‐based subjects). Risk associations were examined using Cox regression analyses. Results: Mean follow‐up was 9.8 and 10.5 years in WECAC and HUSK, respectively. Following adjustments for established CV risk factors and indices of renal function in WECAC, the hazard ratios (HRs) (95% confidence intervals [CIs]) per one standard deviation increase in log‐transformed plasma TMAO were 1.04 (0.97–1.12), 1.06 (0.95–1.18), and 1.03 (0.93–1.13) for all‐cause, CV, and non‐CV mortality, respectively. Essentially similar results were obtained in patients with angiographically significant coronary artery disease and patients with reduced left ventricular ejection fraction. Corresponding HRs (95% CIs) in the HUSK cohort were 1.03 (0.96–1.10), 1.01 (0.89–1.13), and 1.03 (0.95–1.12) for all‐cause‐, CV, and non‐CV mortality, respectively. Conclusions: Circulating TMAO did not predict long‐term all‐cause, CV, or non‐CV mortality in patients with coronary heart disease or in community‐based adults. This large study does not support a role of TMAO for patient risk stratification in primary or secondary prevention. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

40. Predicting sudden cardiac death using common genetic risk variants for coronary artery disease

Author

Hernesniemi, Jussi A., Lyytikäinen, Leo-Pekka, Oksala, Niku, Seppälä, Ilkka, Kleber, Marcus E., Mononen, Nina, März, Winfried, Mikkelsson, Jussi, Pessi, Tanja, Louhelainen, Anne-Mari, Martiskainen, Mika, Nikus, Kjell, Klopp, Norman, Waldenberger, Melanie, Illig, Thomas, Kähönen, Mika, Laaksonen, Reijo, Karhunen, Pekka J., and Lehtimäki, Terho

Published
2015
Full Text
View/download PDF

44. Genome-wide association study on dimethylarginines reveals novel AGXT2 variants associated with heart rate variability but not with overall mortality

Author

Seppälä, Ilkka, Kleber, Marcus E., Lyytikäinen, Leo-Pekka, Hernesniemi, Jussi A., Mäkelä, Kari-Matti, Oksala, Niku, Laaksonen, Reijo, Pilz, Stefan, Tomaschitz, Andreas, Silbernagel, Günther, Boehm, Bernhard O., Grammer, Tanja B., Koskinen, Tuomas, Juonala, Markus, Hutri-Kähönen, Nina, Alfthan, Georg, Viikari, Jorma S.A., Kähonen, Mika, Raitakari, Olli T., März, Winfried, Meinitzer, Andreas, and Lehtimäki, Terho

Published
2014
Full Text
View/download PDF

45. Shared Genetic Susceptibility to Ischemic Stroke and Coronary Artery Disease: A Genome-Wide Analysis of Common Variants

Author

Dichgans, Martin, Malik, Rainer, König, Inke R., Rosand, Jonathan, Clarke, Robert, Gretarsdottir, Solveig, Thorleifsson, Gudmar, Mitchell, Braxton D., Assimes, Themistocles L., Levi, Christopher, O´Donnell, Christopher J., Fornage, Myriam, Thorsteinsdottir, Unnur, Psaty, Bruce M., Hengstenberg, Christian, Seshadri, Sudha, Erdmann, Jeanette, Bis, Joshua C., Peters, Annette, Boncoraglio, Giorgio B., März, Winfried, Meschia, James F., Kathiresan, Sekar, Ikram, M. Arfan, McPherson, Ruth, Stefansson, Kari, Sudlow, Cathie, Reilly, Muredach P., Thompson, John R., Sharma, Pankaj, Hopewell, Jemma C., Chambers, John C., Watkins, Hugh, Rothwell, Peter M., Roberts, Robert, Markus, Hugh S., Samani, Nilesh J., Farrall, Martin, Schunkert, Heribert, Gschwendtner, Andreas, Bevan, Steve, Chen, Yu-Ching, DeStefano, Anita L., Parati, Eugenio A., Quertermous, Tom, Ziegler, Andreas, Boerwinkle, Eric, Holm, Hilma, Fischer, Marcus, Kessler, Thorsten, Willenborg, Christina, Laaksonen, Reijo, Voight, Benjamin F., Stewart, Alexandre F.R., Rader, Daniel J., Hall, Alistair S., and Kooner, Jaspal S.

Published
2014
Full Text
View/download PDF

47. Plasma ceramides independently predict all-cause mortality in men aged 85+.

Author

Strandberg, Timo E, Kivimäki, Mika, Urtamo, Annele, Jyväkorpi, Satu, and Laaksonen, Reijo

Subjects
BIOMARKERS, MEN'S health, CONFIDENCE intervals, MORTALITY, LIQUID chromatography, GERIATRIC assessment, CERAMIDES, RISK assessment, PSYCHOLOGICAL tests, MASS spectrometry, DESCRIPTIVE statistics, LONGITUDINAL method, OLD age
Abstract

Background assessing cardiovascular and mortality risk with conventional biomarkers is challenging in oldest-old due to multimorbidity and polypharmacy. Ceramides are bioactive lipids shown to predict mortality in late middle-aged cohorts. Objective to assess whether plasma ceramides have independent prognostic value for mortality among oldest-old (85+). Design longitudinal cohort study (Helsinki Businessmen Study, HBS) with a 3.5-year follow-up. Setting and subjects survivors of HBS (125 men born in 1919–1934) visited the clinic for laboratory and clinical examination. Methods functional status including physical (short physical performance battery) and Montreal Cognitive Assessment (MoCA) cognitive performance was assessed and laboratory examinations included a large set of biomarkers. Plasma ceramide concentration (Cer(d18:1/16:0)) was measured using a targeted liquid chromatography–tandem mass spectrometry assay. Mortality was retrieved from national registers. Results median age was 88 years, two-thirds had multimorbidity and 59% were on statin treatment. During the follow-up, 22 (18%) men died. In a model adjusted for variables associated with mortality in the whole cohort at P  < 0.20 (log glucose, SPPB, MoCA and statin use), Cer(d18:1/16:0) as a continuous trait was associated with increased mortality: hazard ratio (HR) per 1 SD 1.64 (95% confidence interval [CI] 1.23–2.18). Compared with the bottom tertile of Cer(d18:1/16:0), HR of mortality was 5.44-fold (95% CI 1.17–25.3) in the top tertile. Conclusions these data raise the hypothesis that plasma ceramide concentrations and especially Cer(d18:1/1:60) may offer a clinically useful biomarker to evaluate prognosis in very old age. Such biomarkers are needed for geriatrics, where multimorbidity and pharmacotherapies, such as statins are prevalent hampering assessment of prognosis using conventional methods. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results